Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1999-02

AUTHORS

PJ van Horssen, YVJM van Oosterhout, S Evers, HHJ Backus, MGCT van Oijen, R Bongaerts, T de Witte, FW Preijers

ABSTRACT

Despite the strong in vitro activity of some immunotoxins (ITs), clinical application did not result in complete cure. The outcome of therapy may be improved by combining ITs with IT-cytotoxicity enhancing agents. We studied the effect of various agents that influence the intracellular routing of ITs on the activity of the anti-B cell IT CD22-recombinant (rec) ricin A. In protein synthesis inhibition assays the carboxylic ionophores monensin and nigericin enhanced the activity of the IT 117- and 382-fold, respectively, against the cell line Daudi, and 81- and 318-fold, respectively, against the cell line Ramos. IT activity to Daudi and Ramos was enhanced to a lesser extent by the lysosomotropic amines chloroquine (14- and 11-fold, respectively) and NH4Cl (nine- and 10-fold, respectively). However, the combination of NH4Cl and chloroquine induced more than an additive effect (145- and 107-fold, respectively). Cytotoxicity was not influenced by brefeldin A, all-trans retinoic acid (ATRA), verapamil and perhexiline maleate. Bacitracin enhanced the IT cytotoxicity in contrast to the other protease inhibitors aprotinin, leupeptin and soybean trypsin inhibitor, albeit enhancement was weak (two-fold). The enhancers exerted only a negligible effect on bone marrow progenitor cells. We recently developed a flow cytometric cytotoxicity assay in which cell elimination can be assessed. In order to detect enhancement in this assay, we used 5 x 10(-11) M IT (approximately the 50% protein synthesis inhibiting dose (ID50)). This concentration killed 41% of the Daudi cells and 42% of the Ramos cells. In the presence of 10 nM monensin the IT killed 74% and 99% and in the presence of 10 nM nigericin 96% and 99% of the Daudi and Ramos cells, respectively. At 10(-8) M, CD22-rec ricin A eliminated malignant cells originating from three patients with B-CLL (0.42 log) and two with B-ALL (0.19 log) patients. Cytotoxicity to malignant cells was enhanced by NH4Cl, chloroquine, monensin and nigericin. The combination of NH4Cl and chloroquine enhanced the activity most effectively (up to 2.06 log). To determine the applicability of the IT in combination with enhancers in vivo we investigated the effect of human serum. Human serum inhibited IT activity which could not be restored by monensin and nigericin because of complete inhibition of these enhancers by serum. In contrast, chloroquine partially restored the activity of CD22-rec ricin A in the presence of human serum. We conclude that monensin, nigericin and the combination of NH4Cl and chloroquine can be used instead of NH4Cl to potentiate CD22-rec ricin A activity in purging autologous bone marrow transplants contaminated with malignant B cells. Chloroquine might be a promising enhancer of CD22-rec ricin A for treating patients in vivo. More... »

PAGES

241

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.leu.2401262

DOI

http://dx.doi.org/10.1038/sj.leu.2401262

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052748680

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10025898


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Differentiation, B-Lymphocyte", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Physiological Phenomena", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Purging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Burkitt Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium Channel Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Adhesion Molecules", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lectins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Lymphocytic, Chronic, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoproliferative Disorders", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Synthesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ricin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sialic Acid Binding Ig-like Lectin 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Horssen", 
        "givenName": "PJ", 
        "id": "sg:person.0740323644.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740323644.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Oosterhout", 
        "givenName": "YVJM", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evers", 
        "givenName": "S", 
        "id": "sg:person.01155051441.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155051441.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Backus", 
        "givenName": "HHJ", 
        "id": "sg:person.011214077004.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011214077004.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Oijen", 
        "givenName": "MGCT", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bongaerts", 
        "givenName": "R", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Department of Hematology, University Hospital St Radboud, Nijmegen, The Netherlands", 
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Witte", 
        "givenName": "T", 
        "id": "sg:person.015730551677.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015730551677.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Preijers", 
        "givenName": "FW", 
        "id": "sg:person.01141450140.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141450140.79"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3109/10428199309148526", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003989055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0005-2736(92)90291-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012069472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0005-2736(92)90291-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012069472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.2910560413", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013267082"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00199994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015450416", 
          "https://doi.org/10.1007/bf00199994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00199994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015450416", 
          "https://doi.org/10.1007/bf00199994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1432-1033.1975.tb21001.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026573013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1749-6632.1987.tb45800.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027939455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.2910420527", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030164040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-5793(93)81337-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033571048"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-4827(80)90270-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042454441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.immunol.14.1.49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044390423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.4.292", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059818418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1987.5.4.641", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079821127"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1999-02", 
    "datePublishedReg": "1999-02-01", 
    "description": "Despite the strong in vitro activity of some immunotoxins (ITs), clinical application did not result in complete cure. The outcome of therapy may be improved by combining ITs with IT-cytotoxicity enhancing agents. We studied the effect of various agents that influence the intracellular routing of ITs on the activity of the anti-B cell IT CD22-recombinant (rec) ricin A. In protein synthesis inhibition assays the carboxylic ionophores monensin and nigericin enhanced the activity of the IT 117- and 382-fold, respectively, against the cell line Daudi, and 81- and 318-fold, respectively, against the cell line Ramos. IT activity to Daudi and Ramos was enhanced to a lesser extent by the lysosomotropic amines chloroquine (14- and 11-fold, respectively) and NH4Cl (nine- and 10-fold, respectively). However, the combination of NH4Cl and chloroquine induced more than an additive effect (145- and 107-fold, respectively). Cytotoxicity was not influenced by brefeldin A, all-trans retinoic acid (ATRA), verapamil and perhexiline maleate. Bacitracin enhanced the IT cytotoxicity in contrast to the other protease inhibitors aprotinin, leupeptin and soybean trypsin inhibitor, albeit enhancement was weak (two-fold). The enhancers exerted only a negligible effect on bone marrow progenitor cells. We recently developed a flow cytometric cytotoxicity assay in which cell elimination can be assessed. In order to detect enhancement in this assay, we used 5 x 10(-11) M IT (approximately the 50% protein synthesis inhibiting dose (ID50)). This concentration killed 41% of the Daudi cells and 42% of the Ramos cells. In the presence of 10 nM monensin the IT killed 74% and 99% and in the presence of 10 nM nigericin 96% and 99% of the Daudi and Ramos cells, respectively. At 10(-8) M, CD22-rec ricin A eliminated malignant cells originating from three patients with B-CLL (0.42 log) and two with B-ALL (0.19 log) patients. Cytotoxicity to malignant cells was enhanced by NH4Cl, chloroquine, monensin and nigericin. The combination of NH4Cl and chloroquine enhanced the activity most effectively (up to 2.06 log). To determine the applicability of the IT in combination with enhancers in vivo we investigated the effect of human serum. Human serum inhibited IT activity which could not be restored by monensin and nigericin because of complete inhibition of these enhancers by serum. In contrast, chloroquine partially restored the activity of CD22-rec ricin A in the presence of human serum. We conclude that monensin, nigericin and the combination of NH4Cl and chloroquine can be used instead of NH4Cl to potentiate CD22-rec ricin A activity in purging autologous bone marrow transplants contaminated with malignant B cells. Chloroquine might be a promising enhancer of CD22-rec ricin A for treating patients in vivo.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.leu.2401262", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097065", 
        "issn": [
          "0887-6924", 
          "1476-5551"
        ], 
        "name": "Leukemia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "name": "Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells", 
    "pagination": "241", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fb421ccec012eb992e1030dc4faa0a12dc96bffc2eaa4720737449d15a9422e4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10025898"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8704895"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.leu.2401262"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052748680"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.leu.2401262", 
      "https://app.dimensions.ai/details/publication/pub.1052748680"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000360_0000000360/records_118321_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/2401262"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401262'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401262'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401262'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401262'


 

This table displays all metadata directly associated to this object as RDF triples.

225 TRIPLES      21 PREDICATES      59 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.leu.2401262 schema:about N0fb7829d231340809f9483c08172d6b8
2 N2750f7e0142c40c98966a5afaec3cede
3 N45e03c9090f141bc853c643cb92000b9
4 N49fa05dc475a45738df3d530bc098011
5 N50fe06a93f624159a9ee847dabc817f5
6 N5d99d0b4c1794ea5b9c1e180a56bbd2e
7 N69eb8f0b361c49cfba0371f77b446f9f
8 N6f36b2d3818a474791b9cef562a051ca
9 N72e33b8f0ea848b8ad2c37056cbb271e
10 N7a13fa825cf14645837e7561fb8bd8e1
11 N8a7c4e2fca72470696856bf507ab7ff3
12 N9f05c545f5f14b0dba423d373261e3e4
13 Nb346c847f520403689d82c0b98043687
14 Nc930b9190a804ddebefada86a50c6618
15 Nc95dfb425c044b64915fbf444c7444a3
16 Nf23ac96d9fed40bebc3b002eec52d6e6
17 Nf3bf4269538d487289f68b40376a2a10
18 Nfa9cf8e0723b4a38ac498de2dec12360
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author Nc05b0a78e22f4a2ea95607207362fa50
22 schema:citation sg:pub.10.1007/bf00199994
23 https://doi.org/10.1002/ijc.2910420527
24 https://doi.org/10.1002/ijc.2910560413
25 https://doi.org/10.1016/0005-2736(92)90291-s
26 https://doi.org/10.1016/0014-4827(80)90270-0
27 https://doi.org/10.1016/0014-5793(93)81337-y
28 https://doi.org/10.1093/jnci/85.4.292
29 https://doi.org/10.1111/j.1432-1033.1975.tb21001.x
30 https://doi.org/10.1111/j.1749-6632.1987.tb45800.x
31 https://doi.org/10.1146/annurev.immunol.14.1.49
32 https://doi.org/10.1200/jco.1987.5.4.641
33 https://doi.org/10.3109/10428199309148526
34 schema:datePublished 1999-02
35 schema:datePublishedReg 1999-02-01
36 schema:description Despite the strong in vitro activity of some immunotoxins (ITs), clinical application did not result in complete cure. The outcome of therapy may be improved by combining ITs with IT-cytotoxicity enhancing agents. We studied the effect of various agents that influence the intracellular routing of ITs on the activity of the anti-B cell IT CD22-recombinant (rec) ricin A. In protein synthesis inhibition assays the carboxylic ionophores monensin and nigericin enhanced the activity of the IT 117- and 382-fold, respectively, against the cell line Daudi, and 81- and 318-fold, respectively, against the cell line Ramos. IT activity to Daudi and Ramos was enhanced to a lesser extent by the lysosomotropic amines chloroquine (14- and 11-fold, respectively) and NH4Cl (nine- and 10-fold, respectively). However, the combination of NH4Cl and chloroquine induced more than an additive effect (145- and 107-fold, respectively). Cytotoxicity was not influenced by brefeldin A, all-trans retinoic acid (ATRA), verapamil and perhexiline maleate. Bacitracin enhanced the IT cytotoxicity in contrast to the other protease inhibitors aprotinin, leupeptin and soybean trypsin inhibitor, albeit enhancement was weak (two-fold). The enhancers exerted only a negligible effect on bone marrow progenitor cells. We recently developed a flow cytometric cytotoxicity assay in which cell elimination can be assessed. In order to detect enhancement in this assay, we used 5 x 10(-11) M IT (approximately the 50% protein synthesis inhibiting dose (ID50)). This concentration killed 41% of the Daudi cells and 42% of the Ramos cells. In the presence of 10 nM monensin the IT killed 74% and 99% and in the presence of 10 nM nigericin 96% and 99% of the Daudi and Ramos cells, respectively. At 10(-8) M, CD22-rec ricin A eliminated malignant cells originating from three patients with B-CLL (0.42 log) and two with B-ALL (0.19 log) patients. Cytotoxicity to malignant cells was enhanced by NH4Cl, chloroquine, monensin and nigericin. The combination of NH4Cl and chloroquine enhanced the activity most effectively (up to 2.06 log). To determine the applicability of the IT in combination with enhancers in vivo we investigated the effect of human serum. Human serum inhibited IT activity which could not be restored by monensin and nigericin because of complete inhibition of these enhancers by serum. In contrast, chloroquine partially restored the activity of CD22-rec ricin A in the presence of human serum. We conclude that monensin, nigericin and the combination of NH4Cl and chloroquine can be used instead of NH4Cl to potentiate CD22-rec ricin A activity in purging autologous bone marrow transplants contaminated with malignant B cells. Chloroquine might be a promising enhancer of CD22-rec ricin A for treating patients in vivo.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree true
40 schema:isPartOf N56a929b73fd2493abcf4bad914fc4cb5
41 N91859cb873734e3aa456557f96884cf2
42 sg:journal.1097065
43 schema:name Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells
44 schema:pagination 241
45 schema:productId N289ee5458b4446d0a7f85afbc6bb271c
46 Nb25290d7b1d6459791b5dc0affd83c85
47 Nca1e3cebe77c4864aeb667a6b57737ba
48 Nf5f1b787ea6e4b6c880fd2be081214e3
49 Nfb8ec04f355c4e68a687ff463956649a
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052748680
51 https://doi.org/10.1038/sj.leu.2401262
52 schema:sdDatePublished 2019-04-11T12:05
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher Nbda364f19bdb46a3a2f2acec858964c0
55 schema:url https://www.nature.com/articles/2401262
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N0bb181dae5794291bfa1401b87ca0de9 rdf:first sg:person.015730551677.08
60 rdf:rest Ndafee5f672244ee5b2a41e8435f5943c
61 N0fb7829d231340809f9483c08172d6b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Blood Physiological Phenomena
63 rdf:type schema:DefinedTerm
64 N2332cf2d60f74bdcabd45c0d22362436 rdf:first sg:person.011214077004.08
65 rdf:rest Nf9a9c8067e674d8cbd822364a2ad28a1
66 N2750f7e0142c40c98966a5afaec3cede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Cell Line
68 rdf:type schema:DefinedTerm
69 N289ee5458b4446d0a7f85afbc6bb271c schema:name pubmed_id
70 schema:value 10025898
71 rdf:type schema:PropertyValue
72 N45e03c9090f141bc853c643cb92000b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Bone Marrow Purging
74 rdf:type schema:DefinedTerm
75 N49fa05dc475a45738df3d530bc098011 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Burkitt Lymphoma
77 rdf:type schema:DefinedTerm
78 N50fe06a93f624159a9ee847dabc817f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Sialic Acid Binding Ig-like Lectin 2
80 rdf:type schema:DefinedTerm
81 N56a929b73fd2493abcf4bad914fc4cb5 schema:issueNumber 2
82 rdf:type schema:PublicationIssue
83 N5d99d0b4c1794ea5b9c1e180a56bbd2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Humans
85 rdf:type schema:DefinedTerm
86 N63431153dc9941ff860a0736085fca40 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
87 schema:familyName van Oijen
88 schema:givenName MGCT
89 rdf:type schema:Person
90 N69eb8f0b361c49cfba0371f77b446f9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Antigens, Differentiation, B-Lymphocyte
92 rdf:type schema:DefinedTerm
93 N6f36b2d3818a474791b9cef562a051ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Cell Survival
95 rdf:type schema:DefinedTerm
96 N729c42e0c4ba48fab80ef17636f0d0c8 rdf:first sg:person.01155051441.94
97 rdf:rest N2332cf2d60f74bdcabd45c0d22362436
98 N72e33b8f0ea848b8ad2c37056cbb271e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Leukemia, Lymphocytic, Chronic, B-Cell
100 rdf:type schema:DefinedTerm
101 N7a13fa825cf14645837e7561fb8bd8e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Recombinant Proteins
103 rdf:type schema:DefinedTerm
104 N8a7c4e2fca72470696856bf507ab7ff3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Cell Adhesion Molecules
106 rdf:type schema:DefinedTerm
107 N8c34d44b9134408c96c6f3fe7d653922 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
108 schema:familyName van Oosterhout
109 schema:givenName YVJM
110 rdf:type schema:Person
111 N91859cb873734e3aa456557f96884cf2 schema:volumeNumber 13
112 rdf:type schema:PublicationVolume
113 N957f5a5a35dd4d95923a1f68b1b11a99 rdf:first Nbc4a0f8f7ffc4292b81a15c3760bcb01
114 rdf:rest N0bb181dae5794291bfa1401b87ca0de9
115 N9f05c545f5f14b0dba423d373261e3e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Protein Synthesis Inhibitors
117 rdf:type schema:DefinedTerm
118 Nb25290d7b1d6459791b5dc0affd83c85 schema:name doi
119 schema:value 10.1038/sj.leu.2401262
120 rdf:type schema:PropertyValue
121 Nb346c847f520403689d82c0b98043687 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Antigens, CD
123 rdf:type schema:DefinedTerm
124 Nbc4a0f8f7ffc4292b81a15c3760bcb01 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
125 schema:familyName Bongaerts
126 schema:givenName R
127 rdf:type schema:Person
128 Nbda364f19bdb46a3a2f2acec858964c0 schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 Nc05b0a78e22f4a2ea95607207362fa50 rdf:first sg:person.0740323644.24
131 rdf:rest Nce7aaf1fc9004777af029924ba52fdf6
132 Nc930b9190a804ddebefada86a50c6618 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Lymphoproliferative Disorders
134 rdf:type schema:DefinedTerm
135 Nc95dfb425c044b64915fbf444c7444a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Lectins
137 rdf:type schema:DefinedTerm
138 Nca1e3cebe77c4864aeb667a6b57737ba schema:name dimensions_id
139 schema:value pub.1052748680
140 rdf:type schema:PropertyValue
141 Nce7aaf1fc9004777af029924ba52fdf6 rdf:first N8c34d44b9134408c96c6f3fe7d653922
142 rdf:rest N729c42e0c4ba48fab80ef17636f0d0c8
143 Ndafee5f672244ee5b2a41e8435f5943c rdf:first sg:person.01141450140.79
144 rdf:rest rdf:nil
145 Nf23ac96d9fed40bebc3b002eec52d6e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Ricin
147 rdf:type schema:DefinedTerm
148 Nf3bf4269538d487289f68b40376a2a10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Calcium Channel Blockers
150 rdf:type schema:DefinedTerm
151 Nf5f1b787ea6e4b6c880fd2be081214e3 schema:name nlm_unique_id
152 schema:value 8704895
153 rdf:type schema:PropertyValue
154 Nf9a9c8067e674d8cbd822364a2ad28a1 rdf:first N63431153dc9941ff860a0736085fca40
155 rdf:rest N957f5a5a35dd4d95923a1f68b1b11a99
156 Nfa9cf8e0723b4a38ac498de2dec12360 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Tumor Cells, Cultured
158 rdf:type schema:DefinedTerm
159 Nfb8ec04f355c4e68a687ff463956649a schema:name readcube_id
160 schema:value fb421ccec012eb992e1030dc4faa0a12dc96bffc2eaa4720737449d15a9422e4
161 rdf:type schema:PropertyValue
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
166 schema:name Clinical Sciences
167 rdf:type schema:DefinedTerm
168 sg:journal.1097065 schema:issn 0887-6924
169 1476-5551
170 schema:name Leukemia
171 rdf:type schema:Periodical
172 sg:person.011214077004.08 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
173 schema:familyName Backus
174 schema:givenName HHJ
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011214077004.08
176 rdf:type schema:Person
177 sg:person.01141450140.79 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
178 schema:familyName Preijers
179 schema:givenName FW
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141450140.79
181 rdf:type schema:Person
182 sg:person.01155051441.94 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
183 schema:familyName Evers
184 schema:givenName S
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155051441.94
186 rdf:type schema:Person
187 sg:person.015730551677.08 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
188 schema:familyName de Witte
189 schema:givenName T
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015730551677.08
191 rdf:type schema:Person
192 sg:person.0740323644.24 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
193 schema:familyName van Horssen
194 schema:givenName PJ
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740323644.24
196 rdf:type schema:Person
197 sg:pub.10.1007/bf00199994 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015450416
198 https://doi.org/10.1007/bf00199994
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1002/ijc.2910420527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030164040
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1002/ijc.2910560413 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013267082
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/0005-2736(92)90291-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1012069472
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/0014-4827(80)90270-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042454441
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/0014-5793(93)81337-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1033571048
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1093/jnci/85.4.292 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059818418
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1111/j.1432-1033.1975.tb21001.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026573013
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1111/j.1749-6632.1987.tb45800.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027939455
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1146/annurev.immunol.14.1.49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044390423
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1200/jco.1987.5.4.641 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079821127
219 rdf:type schema:CreativeWork
220 https://doi.org/10.3109/10428199309148526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003989055
221 rdf:type schema:CreativeWork
222 https://www.grid.ac/institutes/grid.10417.33 schema:alternateName Radboud University Nijmegen Medical Centre
223 schema:name Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands
224 Department of Hematology, University Hospital St Radboud, Nijmegen, The Netherlands
225 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...